Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03127709
Other study ID # 17-199
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 7, 2017
Est. completion date April 2025

Study information

Verified date May 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at memory and thinking as well as brain function via MRI scan.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 13
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age greater than or equal to 18 years. - Fluency in English - Diagnosis of a histiocytic disorder as determined, in the opinion of the study PI, by a corroborating constellation of histopathology, clinical, and/or radiologic findings. - Will undergo Standard of Care MRI. Exclusion Criteria: - Known intracranial involvement of histiocytosis (including dura, leptomeninges and brain parenchyma) - Prior stroke or intracranial hemorrhage - Other (non-histiocytic) intracranial neoplasm or neurological disorder deemed by the PI or Co-PI to confound neuroimaging studies (e.g., demyelinating disease) - Existing diagnosis of a psychiatric disorder or untreated mood disturbance - Existing diagnosis of a neurodegenerative disease, such as Alzheimer's disease - Chronic or daily excessive alcohol consumption as determined by the PI. - History of chronic use of corticosteroids, defined as continuous treatment for six months or longer at any time in the past - History of severe claustrophobia or other contraindications to patient SOC brain MRI - Prior intravenous cytarabine or cladribine - Other current or prior treatments (e.g., high-dose chemotherapy for a different cancer) deemed by the PI or Co-PI to confound imaging studies or cognitive performance

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Trail Making Test, Parts A & B
Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
Brief Test of Attention
Assesses auditory working memory
Symbol Span
Assesses visual working memory
Controlled Oral Word Association Test
The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
The Hopkins Verbal Learning Test-Revised
HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
Brief Visuospatial Memory Test-Revised
The BVMT-R is a test of visuospatial learning and memory.
Hospital Anxiety and Depression Scale
The HADS is a brief assessment validated in many cancer populations.
McGill Quality of Life Scale
This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
Diagnostic Test:
MR Brain Imaging
Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
Resting state functional MRI
Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
Behavioral:
Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey
United States Memorial Sloan Kettering Cancer Center @ Suffolk Commack New York
United States Memorial Sloan Kettering Westchester Harrison New York
United States Memorial Sloan Kettering Monmouth Middletown New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary neurocognitive function Neurocognitive tests will yield raw scores that are converted to z-scores, normalized for participant's age, sex and educational level.The proportion of participants demonstrating cognitive impairment (as defined by 2 or more z-scores less than -1.5) will be summarized. Also, the proportion of participants with impairment (z < -1.5) for each cognitive test will be summarized. In this way the cognitive assessment yields a dichotomous outcome of impaired versus not impaired for each participant but also allow for more granular assessment of impairment in specific cognitive domains. 1 year
Primary quality of life questionnaires will yield raw scores (total score for HADS and McGill QOL, as well as anxiety and depression subscores for the HADS). QOL scores will be analyzed as raw scores. Cognitive test scores will be transformed into z-sores (based on score distributions from established normative samples with a mean of 0 and standard deviation of 1) to define the presence/severity of cognitive dysfunction. Scores will be normalized for age, sex and education. 1 year
Primary comparing of grey matter volume In a whole-brain analysis, first, cortical thickness will be compared between participants and controls and regions of statistically significant grey matter loss will be identified. This is done computionally with a whole-brain, vertex-by-vertex approach, as stated above. Also, as stated above (Section 7), statistical significance thresholding is at p<0.001, correcting for multiple comparisons using the False Discovery Rate (FDR) method and clustering thresholds, methods used in various high-throughput contexts, including MRI analysis. 1 year
See also
  Status Clinical Trial Phase
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Recruiting NCT05915208 - Histiocytic Disorder Follow-up Study
Recruiting NCT04437381 - Molecular Targets for the Treatment of Histiocytosis
Terminated NCT01050439 - Unrelated Donor Transplant for Malignant and Non-Malignant Disorders Phase 2
Active, not recruiting NCT00145626 - HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase 2
Not yet recruiting NCT05803629 - Characterizing Histiocytosis With 68Ga-FAPI PET/CT N/A
Recruiting NCT04665674 - Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Terminated NCT02012231 - Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Phase 1
Completed NCT01225718 - Ceftriaxone in Non-neutropenic Fever N/A
Recruiting NCT05786924 - A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Phase 1
Recruiting NCT04943224 - Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients Phase 2
Recruiting NCT04943198 - Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis Phase 2
Recruiting NCT04943211 - Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging Phase 3

External Links